| Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study W Park, DH Yoo, P Miranda, M Brzosko, P Wiland, S Gutierrez-Ureña, ... Annals of the rheumatic diseases 76 (2), 346-354, 2017 | 295 | 2017 |
| A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from … DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Arthritis research & therapy 18, 1-12, 2016 | 200 | 2016 |
| Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis … W Park, DH Yoo, J Jaworski, J Brzezicki, A Gnylorybov, V Kadinov, ... Arthritis research & therapy 18, 1-11, 2016 | 164 | 2016 |
| Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from … W Park, MJ Lim, P Miranda, M Brzosko, P Wiland, S Gutierrez-Urena, ... Arthritis and Rheumatism 65 (12), 2013 | 49 | 2013 |
| OP0068 A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the planetra study DH Yoo, A Racewicz, J Brzezicki, R Yatsyshyn, ET Arteaga, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A73-A73, 2013 | 42 | 2013 |
| FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active … W Park, J Jaworski, J Brzezicki, A Gnylorybov, V Kadinov, IG Sariego, ... Annals of the Rheumatic Diseases 72 (Suppl 3), A516-A517, 2013 | 34 | 2013 |
| AB0860 Impact of treatment with adalimumab on disease activity, work productivity and workday loss in patients with ankylosing spondylitis S Bogdanova, S Dimitrov, S Hristova, T Shivacheva, V Kadinov Annals of the Rheumatic Diseases 71 (Suppl 3), 687-687, 2013 | 1 | 2013 |
| CHANGE IN BMD DURING TREATMENT WITH IBANDRONATE ADMINISTERED INTRAVENOUSLY: RESULTS DURING A PERIOD OF 2 YEARS OF OBSERVATION S Bogdanova, S Dimitrov, S Hristova, T Shivacheva, V Kadinov OSTEOPOROSIS INTERNATIONAL 24, S255-S255, 2013 | | 2013 |
| APPLICATION OF FRACTURE RISK ASSESSMENT TOOL (FRAX) TO PREDICT NEED FOR DXA SCANNING AND TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AT RISK OF OSTEOPOROSIS SH Hristova, SP Dimitrov, S Bogdanova, TK Shivacheva, VN Kadinov OSTEOPOROSIS INTERNATIONAL 23, S178-S179, 2012 | | 2012 |
| COMPLIANCE TO OSTEOPOROSIS TREATMENT-IS THE OSTEOPOROSIS FRACTURE A REASON FOR A BETTER TREATMENT? S Hristova, S Dimitrov, T Shivacheva, V Kadinov OSTEOPOROSIS INTERNATIONAL 22, 279-280, 2011 | | 2011 |
Tanya ShivachevaMedical University, Varna, Bulgaria, Medical Doctor, PhDПотвърден имейл адрес: mu-varna.bg
